FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next >>
 
TXT Biosimilar User Fees Info Collection Revised
01/31/2025
 
 
TXT FDA Alert on Fresenius Kabi Infusion Pumps
01/31/2025
 
 
TXT Neo-Tee T-Piece Resuscitators Recalled
01/31/2025
 
 
TXT Guide on Reducing Sepsis from Cell/Tissue Products
01/31/2025
 
 
TXT Senators Urge PhRMA to Support DTC Advertising Bill
01/31/2025
 
 
TXT Inhibikase Therapeutics Pulls Plug on Parkinson’s Drug
01/30/2025
 
 
TXT Nova Bio Recalls Glucose Meters
01/30/2025
 
 
TXT Trial Speed Seen as Key to Accelerated Approvals
01/30/2025
 
 
TXT Merck Stopping Winrevair Trial as Benefit Is Already Seen
01/30/2025
 
 
TXT Multiple Violations Cited at ProRx Outsourcing Facility
01/30/2025
 
 
TXT Cybersecurity Vulnerabilities in 2 Patient Monitors
01/30/2025
 
 
TXT Committee Chair Struggles to Support Kennedy
01/30/2025
 
 
TXT FDA Clears Roche Lipoprotein (a) Assay
01/29/2025
 
 
TXT Orphan Drug Designation for Marsh Lymphoma Drug
01/29/2025
 
 
TXT Adial Finishes Alcohol Abuse Drug PK Study
01/29/2025
 
 
TXT Trust in Health Agencies Continues Decline: KFF
01/29/2025
 
 
TXT Better Vaccine Communication Needed: Column
01/29/2025
 
 
TXT FDA Modernization Act 3.0 Reintroduced
01/29/2025
 
 
TXT RFK Jr. Grilled by Dems at Confirmation Hearing
01/29/2025
 
 
TXT FDA Accepts BLA for Alvotech’s Simponi BLA
01/29/2025
 
 
TXT Additional Ozempic Indication Approved
01/28/2025
 
 
TXT Enhertu Approval Broadens Breast Cancer Use
01/28/2025
 
 
TXT No Informed Consent at Trial Site: FDA
01/28/2025
 
 
TXT 2 Firms Illegally Selling Biologics: FDA
01/28/2025
 
 
TXT FDA Priority Review for New Merck Welireg Indication
01/28/2025
 
 
TXT AI Optics Handheld Retinal Imager Cleared
01/28/2025
 
 
TXT TerSera Wants Prialt ANDA Conditions
01/28/2025
 
 
TXT RFK Jr.’s Cousin Trashes Him on Eve of Hearing
01/28/2025
 
 
TXT Provepharm Recalls Phenylephrine HCl
01/27/2025
 
 
TXT Once Monthly Leqembi for Alzheimer’s Approved
01/27/2025
 
 
TXT Pfizer Pays $60 million to Settle Biohaven Kickbacks
01/27/2025
 
 
TXT Vanda Files NDA for Motion Sickness Drug
01/27/2025
 
 
TXT Stroke Device Cleared for Larger Catheters
01/27/2025
 
 
TXT Fast Track for Prostate Cancer Imaging Drug
01/24/2025
 
 
TXT ALX Oncology Seeking Accelerated OK for Evorpacept
01/24/2025
 
 
TXT FDA Approves Medexus Leukemia NDA
01/24/2025
 
 
TXT FDA Delays Non-Rx Drug Final Rule
01/24/2025
 
 
TXT CDRH’s Sara Brenner Elevated to Acting Commissioner
01/24/2025
 
 
TXT Keytruda+Lenvima Mixed Data in Gastroesophageal Cancer
01/24/2025
 
 
TXT FDA Extends Review of Stealth Bio NDA
01/23/2025
 
 
TXT Continue Strong Compliance, Quality Programs: Attorneys
01/23/2025
 
 
TXT Implement Digital Technologies Carefully: GE HealthCare
01/23/2025
 
 
TXT FDA Will Review Biogen Spinraza sNDA
01/23/2025
 
 
TXT FDA Removes ‘Diversity’ Docs From Web Site
01/23/2025
 
 
TXT Former FDA Women’s Health Head Wood Dies
01/23/2025
 
 
TXT Durbin, Grassley Reintroduce Drug Ad Price Bill
01/23/2025
 
 
TXT New Copaxone Boxed Warning
01/22/2025
 
 
TXT CBER Approved 67 Products in 2024: Report
01/22/2025
 
 
TXT FDA Wins Vanda Trade Secret Case
01/22/2025
 
 
TXT FDA Union Sues Trump Over Schedule F
01/22/2025
 
 
TXT Temporary Embargo on FDA Communications
01/22/2025
 
 
TXT FDA Lifts Hold on Cialis Rx-to-OTC Study
01/22/2025
 
 
TXT Woodcock Joins Friends of Cancer Research Board
01/22/2025
 
 
TXT Atara, FDA Agree on Steps to Lift Clinical Holds
01/21/2025
 
 
TXT Multiple Incell Violations Cited
01/21/2025
 
 
TXT Amended Sanofi Warning Letter
01/21/2025
 
 
TXT J&J Wins Monotherapy Use for Spravato
01/21/2025
 
 
TXT Biomarker Bioanalytical Method Validation
01/21/2025
 
 
TXT 7 Observations on SCA Pharmaceuticals FDA-483
01/21/2025
 
 
TXT FDA, Other Agencies Ordered Back in Office
01/21/2025
 
 
TXT Replimune BLA for Melanoma Gets Priority Review
01/21/2025
 
 
TXT Amylyx Clinical Hold Lifted on ALS Drug
01/21/2025
 
 
TXT Animal Drug Regs Amended for Recent Approvals
01/17/2025
 
 
TXT Amgen’s Lumakras/Vectibix OK’d in Colon Cancer
01/17/2025
 
 
TXT CDER Commits to 11 Drug Quality Guides in 2025
01/17/2025
 
 
TXT FDA Lifts Alert on Neonatal Incubators
01/17/2025
 
 
TXT AstraZeneca’s Calquence Wins Traditional Approval
01/17/2025
 
 
TXT CDRH Authorized 120 Novel Devices in 2024
01/17/2025
 
 
TXT FDA Seeks Comments on Cannabis Use in Animals
01/16/2025
 
 
TXT Commissioners’ Suggestions for Martin Makary
01/16/2025
 
 
TXT Boehringer Schizophrenia Cognition Trial Misses Endpoints
01/16/2025
 
 
TXT Medline Fluid Delivery Sets Recalled
01/16/2025
 
 
TXT FDA Early Alert on Fresenius Pump Software Updates
01/16/2025
 
 
TXT FDA ‘Complete Response’ on Atara’s Ebvallo
01/16/2025
 
 
TXT Anti-Neuropathy Guidance for Cancer Drugs
01/16/2025
 
 
TXT FDA Policy Head Lands at King & Spalding
01/15/2025
 
 
TXT QS Violations at Xoran Technologies
01/15/2025
 
 
TXT 8 Observations in Phillips Precision Inspection
01/15/2025
 
 
TXT AdvaMed Trial Participation Snapshot Comments
01/15/2025
 
 
TXT Former McKinsey Exec Pleads Guilty in Opioid Case
01/15/2025
 
 
TXT Lilly’s Omvoh Wins Expanded Approval
01/15/2025
 
 
TXT J&J Bladder Cancer Drug Under Review
01/15/2025
 
 
TXT Getinge/Maquet Recalls VasoView HemoPro 2 Devices
01/15/2025
 
 
TXT Vanda Can Seek Tradipitant Hearing: FDA Notice
01/15/2025
 
 
TXT 7 QS Issues at 3 Integra Facilities
01/14/2025
 
 
TXT Hologic QS and MDR Violations
01/14/2025
 
 
TXT 12 No-Longer-Marketed NDAs Withdrawn
01/14/2025
 
 
TXT OIG Faults 3 of 24 FDA Accelerated Approvals
01/14/2025
 
 
TXT Nitrosamine CPCA Expedites Drug Approvals: FDA
01/14/2025
 
 
TXT ANDA Oligonucleotide Guides Needed: AAM
01/14/2025
 
 
TXT Subcutaneous Leqembi BLA Accepted for Review
01/14/2025
 
 
TXT Icotec Carbon Fiber Spinal Infection Implant Cleared
01/14/2025
 
 
TXT Spear Bio Gets Breakthrough Status on Alzheimer's Test
01/14/2025
 
 
TXT Califf Final Essay Touts Covid Vaccines
01/13/2025
 
 
TXT Priority Review for Lung Cancer BLA
01/13/2025
 
 
TXT Philips Recalls ECG Mobile Monitoring App
01/13/2025
 
 
TXT Guide on Device PMA/HDE Modular Reviews
01/13/2025
 
 
TXT Rigel Pharma Gets Orphan Status for R289
01/13/2025
 
 
TXT FDA Turmoil Before Trump: CDER Chief Quits
01/10/2025
 
 
TXT 18,000 ‘Appalled’ Physicians Urge Senate Rejection of RFK Jr.
01/10/2025
 
 
<< Prev  4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving